ArticleActa neuropathologica communications2025
Removal or inhibition of transglutaminase 2 decreases cellular stress, supporting tissue preservation, and recovery after SCI.
Article in Acta neuropathologica communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Tissue engineering for traumatic spinal cord injury: Research advances and clinical translation.Bioactive materials · 2026Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Transglutaminase 2 (TG2) is a multifunctional enzyme widely implicated in neuroinflammation and extracellular matrix (ECM) remodeling after central nervous system (CNS) injury and diseases. In spinal cord injury (SCI), TG2 contributes significantly to pathology through ECM remodeling and glial scar formation. Here, we explored the intracellular roles of TG2 following severe spinal cord compression injury, utilizing TG2 knockout (KO) mice and pharmacological inhibition via cystamine. Genetic deletion or inhibition of TG2 significantly improved locomotor function and promoted enhanced preservation of white and gray matter post-injury. Mechanistically, TG2 KO reduced fibronectin deposition, chondroitin sulfate proteoglycan accumulation, and reactive gliosis. Importantly, imaging mass cytometry revealed that TG2 deletion attenuated cellular stress responses, including reductions in ER stress markers (GRP78), oxidative stress mediators (pNrf2), mitochondrial dysfunction indicators (BNIP3 and cytochrome c), and increased neuronal expression of survival-associated (pREL-NFκB). These results highlight a novel intracellular function for TG2 in exacerbating neurodegeneration through modulation of cellular stress pathways, offering promising therapeutic implications for SCI recovery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.